Baseline and three-month De Ritis ratio and gamma-glutamyltransferase as prognostic biomarkers in metastatic renal cell carcinoma treated with targeted therapy
Elevated De Ritis ratio and GGT values at 3 months were independently associated with both shorter progression‑free survival and overall survival.
The study evaluated baseline and 3‑month liver function test parameters, particularly the De Ritis ratio (AST/ALT) and gamma‑glutamyltransferase (GGT), as prognostic biomarkers in 264 patients with metastatic renal cell carcinoma (mRCC) receiving first‑line targeted therapy. Multivariate analysis demonstrated that elevated De Ritis ratio and GGT at 3 months independently predicted shorter progression‑free survival (PFS) and overall survival (OS). These inexpensive, routinely measured biomarkers may complement existing prognostic models in clinical practice.
The study demonstrates that simple, routinely measured liver function parameters (De Ritis ratio and GGT) can serve as independent prognostic indicators for survival outcomes in metastatic renal cell carcinoma treated with targeted therapy. This finding is clinically relevant because it provides an inexpensive, readily available tool for risk stratification that may influence treatment decisions and patient counseling.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy
- A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions
- EAU 2025: State-of-the-Art Lecture: Neoadjuvant Strategies in Locally Advanced Renal Cancer
- Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics‑based liquid biopsy assay
- Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)